<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256619</url>
  </required_header>
  <id_info>
    <org_study_id>132/793</org_study_id>
    <nct_id>NCT01256619</nct_id>
  </id_info>
  <brief_title>Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The desogestrel (150 mg) in combination with ethinyl estradiol (EE, 30 mg) is known as
      Marvelon in European countries. Previous studies revealed that the Marvelon is good and safe
      for women. As a study from Thailand showed that the Marvelon to be effective and acceptable
      in Thai women. Moreover compared to Caucasian women, the incidences of irregular bleeding and
      side effects were apparently lower in these Asian women . Although Marvelon was used in many
      countries but it's efficacy didn't reported among Iranian women.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum Lipids</measure>
    <time_frame>baseline-1 month &amp; 2month &amp; 3month &amp;6month after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PMS</measure>
    <time_frame>baseline-1 month &amp; 2month &amp; 3month &amp;6month after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Women With PMS</condition>
  <arm_group>
    <arm_group_label>marvelon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marvelon</intervention_name>
    <description>The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest</description>
    <arm_group_label>marvelon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        being on married, being within 18-40 years old, having normal Body mass index (ranged from
        20 to 27 kg/m2), don't use any OCP during 3 months ago, having a normal menstruation cycle
        for the last three cycles, having at least one of following mental and behavioural symptoms
        ( Fatigue, mood changes, lack of energy, irritability, aggression, depression, decreased
        concentration, decreased social relationships, having a greed and increased appetite to
        eating food), having at least one of following physical symptoms (Breast sensitivity,
        swelling and flatulence) and women tend to use OCP for six consecutive months.

        Exclusion Criteria:

        pregnancy, having Anorexia or Bulimia, doing breastfeeding, smoke cigarette, Taking
        sleeping pills more than 3 days per month, Injection estrogen, progesterone or androgen
        during the past 3 months, Contraindications for OCP (including: thrombophlebitis - Severe
        liver disease - cerebrovascular accident and heart disease - unexplained uterine bleeding -
        lupus - breast cancer - migraines - sickle cell anemia - Epilepsy - gallbladder disease -
        kidney problems - varicocele and family history thrombosis).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>seed yekaninejad, PhD</last_name>
    <email>yekaninejad@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tehran University of Medical Sciences-BASIR center</name>
      <address>
        <city>Tehran</city>
        <zip>61-14185</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>abbas noroozi, PhD</last_name>
      <phone>009802166581560</phone>
      <email>noroozia@tums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Abbas noroozi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr.abbas noroozi</name_title>
    <organization>BASIR center</organization>
  </responsible_party>
  <keyword>Marvelon</keyword>
  <keyword>PMS</keyword>
  <keyword>serum Lipids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

